The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Headache with the features of migraine without aura usually follows the aura symptoms. Less commonly, headache lacks migrainous features or is completely absent. Previously it was called classic ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

After adjusting for potential confounders (age, sex, race, use of birth control, pregnancy), findings showed propranolol use was associated with a significant reduction in the risk of stroke among ...

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of ...

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication. The FDA has approved ...

Propranolol, a beta blocker medication used for treating high blood pressure and preventing migraines, may lower ischemic ...

For patients with migraine, the clinical benefits of propranolol, a beta-blocker medication, may extend beyond just migraine ...

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...